Biotech entity
Every one of those 1 sits in a single category, pharma. Zhenya Lindgardt is most often covered alongside PRIME study, which appears in 1 of these 1 story. Each story carries 6 original sources on average, compared with 2.6 for the broader beat in this window.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Zhenya Lindgardt is most often covered alongside PRIME study, which appears in 1 of these 1 story. Each story carries 6 original sources on average, compared with 2.6 for the broader beat in this window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 1 Biotech story that mention Zhenya Lindgardt, all published on March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Zhenya Lindgardt. Shared-story counts are live from our verified record — not editorial picks.
Cash Runway Limit
Current capital projected to fund operations through this period across commercial milestones.
Commercial Target
Goal to reach 15-17 states and 5-7 live partner programs.
Q4 Earnings Call
Management confirms runway through 2028 and details PRIME study impact.
Fiscal Year End
Sera concludes 2025 with $95.8M in cash and a narrowed net loss.
Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. The company is pivoting toward large-scale commercialization of its PreTRM test following landmark PRIME study data showing a 56% reduction in very early preterm births.
Zhenya Lindgardt is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
